The inherited genetic component of sporadic pancreatic adenocarcinoma

Pancreatology

Volumn 9, Issue 3, 2009, Pages 206-214

  Milne, R L ^a   Greenhalf, W ^b   Murta Nascimento, C ^c   Real, F X ^a   Malats, N ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

Etiology; Genetic epidemiology; Genetic susceptibility; Polymorphism; Sporadic pancreatic cancer

Indexed keywords

CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; DNA REPAIR; ENVIRONMENTAL EXPOSURE; GENE INTERACTION; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC VARIABILITY; GENETICS; GENOME; HEREDITY; HUMAN; INFLAMMATION; MITOCHONDRION; MUTATION; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PENETRANCE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE;

EID: 63649161015     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000210261     Document Type: Article

References (90)

1. Soler M, Porta M, Malats N, et al: Learning from case reports: diagnostic issues in an epidemiologic study of pancreatic cancer. J Clin Epidemiol 1998;51:1215-1221.
2. Alderson D, Johnson CD, Neoptolemos JP: Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut 2005;54(suppl 5):v1-v16.
3. Ghaneh P, Costello E, Neoptolemos JP: Biology and management of pancreatic cancer. Gut 2007;56:1134-1152.
4. Ferlay J, Bray F, Pisani P, et al: GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. Lyon, IARC Press, 2004.
5. Sahmoun AE, D'Agostino RA Jr, Bell RA, et al: International variation in pancreatic cancer mortality for the period 1955-1998. Eur J Epidemiol 2003;18 :801-816.
6. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
7. Anderson KE, Mack T, Silverman D: Cancer of the pancreas;in Schottenfeld D, Fraumeni JF Jr (eds): Cancer Epidemiology and Prevention. New York, Oxford University Press, 2006.
8. IARC:Tobacco smoking;in International Agency for Research on Cancer:IARC Monographs of the Evaluation of Carcinogenic Risk of Chemicals to Man. Lyon, IARC, 1986, vol 38.
9. Lowenfels AB, Maisonneuve P, Cavallini G, et al: Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993;328:14 33- 14 3 7.
10. Stevens RJ, Roddam AW, Beral V:Pancreatic cancer in type 1 and young-onset diabetes:systematic review and meta-analysis. Br J Cancer 2007;96:507-509.
11. Del Chiaro M, Zerbi A, Falconi M, et al: Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma. Pancreatology 2007;7:459-469.
12. Klein AP, Beaty TH, Bailey-Wilson JE, et al: Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 2002;23:133-149.
13. Ghadirian P, Boyle P, Simard A, et al: Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int J Pancreatol 1991;10:183-196.
14. McWilliams RR, Rabe KG, Olswold C, et al: Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer 2005;104:388-394.
15. Fernandez E, La Vecchia C, D'Avanzo B, et al: Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol Biomarkers Prev 1994;3:209-212.
16. Tersmette AC, Petersen GM, Offerhaus GJ, et al: Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001;7:738-744.
17. Giardiello FM, Brensinger JD, Tersmette AC, et al: Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119 :14 4 7-14 53.
18. Giardiello FM, Offerhaus GJ, Lee DH, et al: Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993;34:1394-1396.
19. Hahn SA, Greenhalf B, Ellis I, et al: BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 20 03;95:214-221.
20. Hisada M, Garber JE, Fung CY, et al: Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606-611.
21. Lynch HT, Brand RE, Hogg D, et al: Pheno-typic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinomaprone families:the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 20 02;94:84-96.
22. Lynch HT, Smyrk T, Lynch J:An update of HNPCC (Lynch syndrome). Cancer Genet Cytogenet 1997;93:84-99.
23. Sheldon CD, Hodson ME, Carpenter LM, et al: A cohort study of cystic fibrosis and malignancy. Br J Cancer 1993;68:1025-1028.
24. Thompson D, Easton DF:Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358-1365.
25. Vasen HF, Gruis NA, Frants RR, et al: Risk of developing pancreat ic cancer in fa mi lies w ith familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000;87:809-811.
26. Efthimiou E, Crnogorac-Jurcevic T, Lemoine NR:Pancreatic cancer genetics. Pancreatology 2001;1:571-575.
27. Wong T, Howes N, Threadgold J, et al: Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients. Pancreatology 2001;1:486-509.
28. Lynch HT, Brand RE, Deters CA, et al: Hereditary pancreatic cancer. Pancreatology 2001;1:466-471.
29. Eberle MA, Pfutzer R, Pogue-Geile KL, et al: A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. Am J Hum Genet 2002;70:1044-1048.
30. Botstein D, Risch N:Discovering genotypes underlying human phenotypes:past successes for mendelian disease, future approaches for complex disease. Nat Genet 2003;(suppl):228-237.
31. Houlston RS, Peto J:The search for low-penetrance cancer susceptibility alleles. Oncogene 2004;23:6471-6476.
32. Risch NJ:Searching for genetic determinants in the new millennium. Nature 2000;405:847-856.
33. Zondervan KT, Cardon LR:The complex interplay among factors that influence allelic association. Nat Rev Genet 2004;5:89-100.
34. Duell EJ, Holly EA, Bracci PM, et al: A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J Nat l Cancer Inst 2002;94:297-306.
35. Li D, Jiao L, Li Y, et a l:Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 2006;27:1 0 3-111.
36. Jiao L, Bondy ML, Hassan MM, et al: Glutathione S-transferase gene polymorphisms and risk and survival of pancreatic cancer. Cancer 2007;109:840-848.
37. Duell EJ, Holly EA, Bracci PM, et al: A population-based study of the Arg399Gln polymorphism in X-ray repair cross-complementing group 1 (XRCC1) and risk of pancreatic adenocarcinoma. Cancer Res 2002;62:4630-4636.
38. Jiao L, Bondy ML, Hassan MM, et al: Selected polymorphisms of DNA repair genes and risk of pancreatic cancer. Cancer Detect Prev 2006;30:284-291.
39. Jiao L, Hassan MM, Bondy ML, et al: The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. Cancer Lett 2007;245:61- 6 8.
40. Jiao L, Hassan MM, Bondy ML, et al: XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer. Am J Gastroenterol 2008;103:360-367.
41. Duell EJ, Casella DP, Burk RD, et al: Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:726-731.
42. Li D, Ahmed M, Li Y, et al: 5,10-Methylenetetrahydrofolate reductase polymorphisms and the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1470-1476.
43. Wang L, Miao X, Tan W, et al: Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer. Clin Gastroenterol Hepatol 2005;3:743-751.
44. Matsubayashi H, Skinner HG, Iacobuzio-Donahue C, et al: Pancreaticobiliary cancers with deficient methylenetetrahydrofolate reductase genotypes. Clin Gastroenterol Hepatol 2005;3:752-760.
45. Larsson SC, Giovannucci E, Wolk A:Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer:a meta-analysis. Gastroenterology 2006;131:1271-1283.
46. Wang L, Bamlet WR, de Andrade M, et al: Mitochondrial genetic polymorphisms and pancreatic cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:1455-1459.
47. Ayaz L, Ercan B, Dirlik M, et al: The association between N-acetyltransferase 2 gene polymorphisms and pancreatic cancer. Cell Biochem Funct 2008;26:329-333.
48. Bartsch DK, Fendrich V, Slater EP, et al: RNASEL germline variants are associated with pancreatic cancer. Int J Cancer 2005;117:718-722.
49. Bartsch H, Malaveille C, Lowenfels AB, et al: Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase in relation to malignant and benign pancreatic disease risk. The International Pancreatic Disease Study Group. Eur J Cancer Prev 1998;7:215-223.
50. Ockenga J, Vogel A, Teich N, et al: UDP glucuronosyltransferase (UGT1A7) gene polymorphisms increase the risk of chronic pancreatitis and pancreatic cancer. Gastroenterology 2003;124:1802-1808.
51. Olson SH, Orlow I, Simon J, et al: Allergies, variants in IL-4 and IL-4R αgenes, and risk of pancreatic cancer. Cancer Detect Prev 2007;31:345-351.
52. Wheatley-Price P, Asomaning K, Reid A, et al: Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma. Cancer 2008;112:1037-1042.
53. Wang L, Lin DX, Lu XH, et al: Polymorphisms of the DNA repair genes XRCC1 and XPC:relationship to pancreatic cancer risk (in Chinese). Wei Sheng Yan Jiu 2006;35:534-536.
54. Piepoli A, Gentile A, Valvano MR, et al: Lack of association between UGT1A7, UGT1A9, ARP, SPINK1 and CFTR gene polymorphisms and pancreatic cancer in Italian patients. World J Gastroenterol 2006;12:6343-6348.
55. Lee HC, Yoon YB, Kim CY:Association between genetic polymorphisms of the cytochromes P-450 (1A1, 2D6, and 2E1) and the susceptibility to pancreatic cancer. Korean J Intern Med 1997;12:128-136.
56. Verlaan M, Drenth JP, Truninger K, et al: Polymorphisms of UDP-glucuronosyltrans-ferase 1A7 are not involved in pancreatic diseases. J Med Genet 2005;42:e62.
57. Hucl T, Kylanpaa-Back ML, Witt H, et al: HFE genotypes in patients with chronic pancreatitis and pancreatic adenocarcinoma. Genet Med 2007;9:479-483.
58. Liu G, Ghadirian P, Vesprini D, et al: Polymorphisms in GSTM1, GSTT1 and CYP1A1 and risk of pancreatic adenocarcinoma. Br J Cancer 2000;82:1646-1649.
59. Sharer N, Schwarz M, Malone G, et al: Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 19 98;339:645-652.
60. Malats N, Casals T, Porta M, et al: Cystic fi-brosis transmembrane regulator Deltaf508 mutation and 5T allele in patients with chronic pancreatitis and exocrine pancreatic cancer. PANKRAS II Study Group. Gut 2001;48:70-74.
61. Mat subayashi H, Fukushima N, Sato N, et al: Polymorphisms of SPINK1 N34S and CFTR in patients with sporadic and familial pancreatic cancer. Cancer Biol Ther 2003;2:652-655.
62. McWilliams R, Highsmith WE, Rabe KG, et al: Cystic fibrosis transmembrane regulator gene carrier status is a risk factor for young onset pancreatic adenocarcinoma. Gut 2005;54:1661-1662.
63. Couch FJ, Johnson MR, Rabe K, et al: Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 2005;65:383-386.
64. Goggins M, Schutte M, Lu J, et al: Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-5364.
65. Van der Heijden MS, Yeo CJ, Hruban RH, et al: Fanconi anemia gene mutations in youngonset pancreatic cancer. Cancer Res 2003;63:2585-2588.
66. Howes N, Lerch MM, Greenhalf W, et al: Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004;2:252-261.
67. Rebours V, Boutron-Ruault MC, Schnee M, et al: Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis:a national exhaustive series. Am J Gastroenterol 2008;103:111-119.
68. Ghazale A, Chari S:Is autoimmune pancreatitis a risk factor for pancreatic cancer? Pancreas 2007;35:376.
69. Cavestro GM, Frulloni L, Nouvenne A, et al: Association of keratin-8 gene mutation with chronic pancreatitis. Dig Liver Dis 2003;35:416-420.
70. Lempinen M, Paju A, Kemppainen E, et al: Mutations N34S and P55S of the SPINK1 gene in patients with chronic pancreatitis or pancreatic cancer and in healthy subjects:a report from Finland. Scand J Gastroenterol 2005;40:225-230.
71. Teich N, Schulz HU, Witt H, et al: N34S, a pancreatitis associated SPINK1 mutation, is not associated with sporadic pancreatic cancer. Pancreatolog y 2003;3:67-68.
72. Treiber M, Schulz HU, Landt O, et al: Keratin-8 sequence variants in patients with pancreatitis and pancreatic cancer. J Mol Med 2006;84:1015-1022.
73. Li D, Frazier M, Evans DB, et al: Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol 2006;24:1720-1728.
74. Li D, Li Y, Jiao L, et al: Effects of base excision repair gene polymorphisms on pancreatic cancer survival. Int J Cancer 2007;120:1748-1754.
75. Li D, Liu H, Jiao L, et al: Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. Cancer Res 2006;66:3323-3330.
76. Chen J, Li D, Wei C, et al: Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians. Clin Cancer Res 2007;13:3100-3104.
77. Barber MD, Powell JJ, Lynch SF, et al: A polymorphism of the interleukin-1βgene influences survival in pancreatic cancer. Br J Cancer 2000;83:1443-1447.
78. Halma MA, Wheelhouse NM, Barber MD, et al: Interferon-gamma;polymorphisms correlate with duration of survival in pancreatic cancer. Hum Immunol 2004;65:1405-1408.
79. Kaifi JT, Cataldegirmen G, Wachowiak R, et al: Short tandem repeat polymorphisms of exon 4 in Kazal-type gene ECRG2 in pancreatic carcinoma and chronic pancreatitis. Anticancer Res 2007;27:69-73.
80. Easton DF, Pooley KA, Dunning AM, et al: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-1093.
81. McCarthy MI, Abecasis GR, Cardon LR, et al: Genome-wide association studies for complex traits:consensus, uncertainty and challenges. Nat Rev Genet 2008;9:356-369.
82. Christensen K, Murray JC:What genome-wide association studies can do for medicine. N Engl J Med 2007;356:1094-1097.
83. Yeager M, Orr N, Hayes RB, et al: Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645-649.
84. Stacey SN, Manolescu A, Sulem P, et al: Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2007;39:865-869.
85. Estivill X, Armengol L:Copy number variants and common disorders:filling the gaps and exploring complexity in genome-wide association studies. PLoS Genet 2007;3:1787-1799.
86. The Wellcome Trust Case Control Consortium:Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-678.
87. Wacholder S, Chanock S, Garcia-Closas M, et al: Assessing the probability that a positive reportisfalse:an approach for molecularep-idemiology studies. J Natl Cancer Inst 2004;96:434-442.
88. Malats N:Gene-environment interactions in pancreatic cancer. Pancreatology 2001;1:472-476.
89. Garcia-Closas M, Malats N, Silverman D, et al: NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer:results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005;366:649-659.
90. Antoniou AC, Spurdle AB, Sinilnikova OM, et al: Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008;82:937-948.